RBC Capital analyst Gregory Renza maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $362.00. The company’s shares closed last Friday at $316.98. According to ...
C3G is estimated to affect around one person per million in the US, a small patient population, but is one of a series of ...
Big Tech earnings this week could drive markets, as Meta, Apple, and Amazon prepare to reveal AI and growth strategies amid ...
Apple, Microsoft, Alphabet, Amazon, and Meta Platforms will remain in focus as these firms will release their third quarter ...
In a first renal outcome trial of its kind, the SGLT2 inhibitor showed favorable outcomes in the most advanced stages of CKD.
The global antibody therapy market is on the brink of remarkable expansion, driven by rapid advancements in immunotherapy and a surge in demand for innovative treatments for critical conditions, ...
On top of this, a stock split generally shows a company is confident about the future, with the idea that the stock could ...
AbbVie (ABBV) to acquire Aliada Therapeutics for $1.4B in cash, enhancing focus on Alzheimer's disease with innovative ...
Plus, tech, pharma and oil lead the earnings run, Bank of Japan makes a rate call and Britain’s opposition party picks a new leader ...
The leading Melanoma Companies such as IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback